Immune Therapy Produces Anti-Cancer Responses in Advanced Cervical Cancer

Adoptive T-cell therapy ACT appears to provide anti-cancer responses among patients with advanced cervical cancer for whom standard therapy has stopped working These results were published in the Journal of Clinical Oncology The most common cause of cervi [...]

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed

Small phase one trial of a dendritic cell vaccine supports further study in larger trials A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination [...]

Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy ipilumamab and Opdivo nivolumab combinations has just been reported The two-year survival rates were 64 for the Opdivo plus Yervoy combination 59 for Opdivo alone and [...]

Tagrisso Approved for Treatment of Certain Lung Cancers

The US Food and Drug Administration granted regular approval to Tagrisso osimertinib for the treatment of patients with metastatic epidermal growth factor receptor EGFR T790M mutation-positive non-small cell lung cancer NSCLC as detected by an FDA-approve [...]

Breast cancer rates increasing among Asian Americans

Researchers examined breast cancer incidence rates among seven Asian American ethnic groups in this new study In contrast to other US racialethnic groups Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years To be [...]

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer

Treatment with the immune checkpoint inhibitor Opdivo nivolumab yielded durable responses in some patients with advanced non-small cell lung cancer NSCLC with a five-year survival rate of 16 percent according to data presented here at the AACR Annual Meet [...]

Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer

The investigative agent Tecentriq atezolizumb in addition to the chemotherapy agent Abraxane nab-paclitaxel provides high anti-cancer responses among patients with triple-negative breast cancer Approximately 10-20 of breast cancers are referred to as trip [...]

Keytruda Shows Promise in Treatment of Mesothelioma

Keytruda pembrolizumab an antibody drug already used to treat other forms of cancer can be effective in the treatment of the most common form of mesothelioma according to a new study led by investigators from the Perelman School of Medicine at the Univers [...]

Niraparib Approved for Ovarian Cancer Maintenance Treatment

Zejula Niraparib has been approved by the US Food and Drug Administration FDA for use as maintenance therapy in patients with recurrent epithelial ovarian fallopian tube or primary peritoneal who are in complete or partial response to platinum-based chemo [...]

FDA Approves Bavencio as First Treatment for Merkel Cell Cancer

The US Food and Drug Administration today granted accelerated approval to Bavencio avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma MCC including those who have not received prior chemoth [...]